Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Citi initiates coverage on 5 new biotech stocks

2 Top Growth Stocks to Buy on the Dip

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Regeneron Announces Investor Conference Presentations

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?